Improving UI content. Improving Slovenia translation Correct Astra 19.2E satellite name on loading bar. Fix TURKSAT 42E channel not found, if it is not in the first position.

Data Continue to Demonstrate the Durability and Safety of a Novel Gene Therapy Approach to Treating Wet AMD MENLO PARK, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, today will present updated preclinical data on ADVM-022 in non-human primate models of wet AMD (wAMD). Vascular endothelial growth factor (VEGF) overexpression plays a key role in the development and progression of wAMD as well as other retinal conditions.

ADVM-022 utilizes a novel vector designed to allow for intravitreal delivery of gene sequences encoding an inhibitor of VEGF activity. Intravitreal delivery is the route of administration for current standard of care anti-VEGF therapies, and is preferred over invasive surgical subretinal delivery of gene sequences. Mehdi Gasmi, Ph.D., Chief Science and Technology Officer at Adverum will present updated data today at 2 p.m.

ET at the Targeting Ocular Disorders conference taking place in Boston, MA September 27–28, 2017. Previously reported data using the industry standard, laser-induced choroidal neovascularization (CNV) model in a non-human primate study demonstrated that a single intravitreal administration of ADVM-022 had comparable efficacy in reducing grade IV CNV lesions to an intravitreal injection of standard-of-care anti-VEGF therapies. In addition, data showed durable anti-VEGF protein expression with therapeutic protein levels at least 20 weeks after a single intravitreal administration of ADVM-022. Today, additional pharmacokinetic data are being presented, demonstrating sustained expression for 52 weeks, with only mild ocular inflammation following a single intravitreal administration of ADVM-022 in one non-human primate. In a separate study, sustained expression for at least seven months has been observed in several non-human primates.

Adverum will continue to monitor these non-human primates to assess long-term durability of sustained expression of anti-VEGF protein after a single administration of ADVM-022. “These additional long-term data continue to demonstrate sustained expression of anti-VEGF protein and that our novel vector enables intravitreal delivery,” said Amber Salzman, Ph.D., president and chief executive officer of Adverum Biotechnologies.

“Today, patients living with wAMD undergo frequent intravitreal injections, which can increase the burden of managing this disease and poor compliance with treatment can lead to vision loss. We believe the potential of a single intravitreal injection will be of great benefit to patients and clinicians.” About Adverum Biotechnologies, Inc. Adverum is a gene therapy company advancing novel medicines that may offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.

Congratulations you have successfully installed the Knowledge Base Mod. Skachatj propisi dlya detej pechatnie bukvi. Welcome to Knowledge Base Mod!

Pixies discography. Jump to navigation Jump to search. Pixies discography; The Pixies in. Joey Santiago, Kim Deal and David Lovering issued a download-only single, 'Bam Thwok,' and Warren Zevon cover, 'Ain't That Pretty At All', as well as collaborating with Disc Live to release a number of reunion tour live albums in the same year. Pixies discography wikipedia.

Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development.

For more information please visit. Adverum Contact: Charles Butler Vice President, Investor Relations & Corporate Communications 650-272-6260 Source: Adverum Biotechnologies, Inc.

• Pichlmair, Martin 2015-01-01 Creating a simulation of Democracy and its future challenges is a fruitful exercise in design. This short paper describes a different use of a simulation that the traditional training via playing. Instead of playing, the creation of the simulation is at the center of attention. • Saad, Amir Putra Bin Md; Harun, Muhamad Noor; Kadir, Mohammed Rafiq Abdul 2016-01-01 This book develops and analyses computational wear simulations of the total ankle replacement for the stance phase of gait cycle. The emphasis is put on the relevant design parameters. The book presents a model consisting of three components; tibial, bearing and talar representing their physiological functions.

• Kappler, J. R.; Folsom, A. 1972-01-01 Maintainability must be designed into long-duration spacecraft and equipment to provide the required high probability of mission success with the least cost and weight. The ability to perform repairs quickly and easily in a space environment can be achieved by imposing specific maintainability design criteria on spacecraft equipment design and installation. A study was funded to investigate and define design criteria for electronic equipment that would permit rapid removal and replacement in a space environment. The results of the study are discussed together with subsequent simulated zero-g demonstration tests of a mockup with new concepts for packaging.